Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 3:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–2 of 2 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Non-Small Cell Lung Cancer ROS Marker Positive Clear all

Active, not recruiting Phase 1 Interventional

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

NCT02321501

View directory record Official record

Conditions: ALK Positive, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, ROS1 Gene Rearrangement, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions: Ceritinib, Everolimus, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Source: ClinicalTrials.gov public record

Updated May 19, 2026 · Synced May 22, 2026, 3:48 AM EDT

Completed Phase 1 Interventional Results available

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

NCT00585195

View directory record Official record

Conditions: Non-Small Cell Lung Cancer ALK-positive, Non-Small Cell Lung Cancer c-Met Dependent, Non-Small Cell Lung Cancer ROS Marker Positive, Systemic Anaplastic Large-Cell Lymphoma, Advanced Malignancies Except Leukemia
Interventions: PF-02341066, Rifampin, Itraconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older

Enrollment: 596 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2022
U.S. locations: 24
States / cities: Orange, California • Aurora, Colorado • Chicago, Illinois + 8 more

Source: ClinicalTrials.gov public record

Updated Feb 7, 2023 · Synced May 22, 2026, 3:48 AM EDT